Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nabilone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 12/20 | 1.00 |
| ▸ | CNR2 | P34972 | 14/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nabilone SCHEMBL33339 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL17223864 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL29475614 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL2762240 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL563809 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL13759779 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL11615666 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL29448222 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL15520922 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL11615083 | 0.99 | CNR2 (0.98) | CNR2CNR1NR1I2ADORA3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0004753-B1 | PREPARATION OF TETRAHYDROBENZOXOCINS AND CIS-HEXAHYDRODIBENZOPYRANONES | ELI LILLY AND COMPANY (US) | 1982-05-26 | — | — | EP | claimed |
| US-4148809-A | Process for preparing dl-cis-1-hydroxy-3-substituted-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-ones | ELI LILLY AND COMPANY (US) | 1979-04-10 | — | — | US | claimed |
| US-4102902-A | Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor | ELI LILLY AND COMPANY (US) | 1978-07-25 | — | — | US | claimed |
| US-4054582-A | Process for converting cis-hexahydrodibenzo[b,d]pyran-9-ones to trans-hexahydrodibenzo[b,d]-pyran-9-ones | ELI LILLY AND COMPANY (US) | 1977-10-18 | — | — | US | claimed |
| US-4054581-A | Preparation of cis-1-hydroxy-3-substituted-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-ones and intermediates therefor | ELI LILLY AND COMPANY (US) | 1977-10-18 | — | — | US | claimed |
| US-20210198223-A1 | METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL | CORBUS PHARMACEUTICALS, INC. | 2021-07-01 | — | — | US | disclosed |
| US-8258322-B2 | Synthesis of hexahydrodibenzopyranones | WATSON LABORATORIES, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258322-B2 | Synthesis of hexahydrodibenzopyranones | WATSON LABORATORIES, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20100056811-A1 | Synthesis of Hexahydrodibenzopyranones | WATSON LABORATORIES, INC. | 2010-03-04 | — | — | US | disclosed |
| US-20100056811-A1 | Synthesis of Hexahydrodibenzopyranones | WATSON LABORATORIES, INC. | 2010-03-04 | — | — | US | disclosed |
| WO-2010022520-A1 | IMPROVED SYNTHESIS OF HEXAHYDRODIBENZOPYRANONES | DALTON CHEMICAL LABORATORIES INC. (CA) | 2010-03-04 | — | — | WO | disclosed |
| EP-0003883-B1 | AMINO-DIBENZOPYRANS, THEIR PREPARATION, FORMULATIONS CONTAINING THEM AND THEIR USE AS PHARMACEUTICALS | ELI LILLY AND COMPANY (US) | 1982-10-06 | — | — | EP | disclosed |
| US-4087547-A | Hexahydro-dibenzo[b,d]pyran-9-ones in treatment of glaucoma | ELI LILLY AND COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
| US-4054582-A | Process for converting cis-hexahydrodibenzo[b,d]pyran-9-ones to trans-hexahydrodibenzo[b,d]-pyran-9-ones | ELI LILLY AND COMPANY (US) | 1977-10-18 | — | — | US | disclosed |
| US-4054581-A | Preparation of cis-1-hydroxy-3-substituted-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-ones and intermediates therefor | ELI LILLY AND COMPANY (US) | 1977-10-18 | — | — | US | disclosed |
| US-4024275-A | Method of reducing elevated blood pressure with dihydroxy-hexahydrodibenzo(b,d)pyrans | ELI LILLY AND COMPANY (US) | 1977-05-17 | — | — | US | disclosed |
| US-3987188-A | Hexahydro-dibenzo[b,d]pyran-9-ones as sedative drugs | ELI LILLY AND COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
| US-3968125-A | Dihydroxyhexahydrodibenzo[b,d]pyrans | ELI LILLY AND COMPANY (US) | 1976-07-06 | — | — | US | disclosed |
| US-3953603-A | Hexahydro-dibenzo[b,d,]pyran-9-ones as psychotropic, particularly anti-depressant drugs | ELI LILLY AND COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
| US-3944673-A | Hexahydro-dibenzo[b,d]pyran-9-ones as analgesic drugs | ELI LILLY AND COMPANY (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198223-A1 | METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL | CNR1, DHCR24, CNR2 | CNR1 1/4885CNR2 3/4885NR1I2 460/4885 |
| US-20100056811-A1 | Synthesis of Hexahydrodibenzopyranones | GNE, GALE, UGDH | CNR1 8/4885CNR2 6/4885NR1I2 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.